UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 29, 2020
SIGA TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission file number)
|
(I.R.S. employer identification no.)
|
|
31 East 62nd Street
New York, New York
(Address of principal executive offices)
|
10065
(Zip code)
|
Registrant’s telephone number, including area code: (212) 672-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
common stock, $.0001 par value
|
SIGA
|
The Nasdaq Global Market
|
| Item 8.01 |
Other Events.
|
On April 29, 2020, SIGA Technologies, Inc., a Delaware corporation, issued a press release entitled “SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the
Procurement of Oral TPOXX®”.
The full text of the Press Release is attached as Exhibit 99.1 hereto and incorporated herein by reference.
| Item 9.01. |
Financial Statements and Exhibits
|
(d) The following exhibits are included in this report:
|
Exhibit
No.
|
Description
|
|
Press Release, dated April 29, 2020.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
SIGA TECHNOLOGIES, INC.
|
|||
|
By:
|
/s/ Daniel J. Luckshire | ||
|
Name:
|
Daniel J. Luckshire
|
||
|
Title:
|
Chief Financial Officer
|
||
|
Date: April 29, 2020
|
|||
Exhibit 99.1
SIGA Announces BARDA Exercise of Contract Options
Valued at $101.3 Million for the Procurement of Oral
TPOXX
®
Deliveries to Maintain National Security
Expected to Start in Second Quarter 2020
April 29, 2020
NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options under its 2018 Biomedical Advanced
Research and Development Authority (BARDA) contract (“19C BARDA Contract”) worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox (tecovirimat). Deliveries of oral TPOXX to maintain national
preparedness under these option exercises are expected to start in the second quarter of 2020 and be completed by April 2021. With the above-mentioned exercise of options, all procurement options under CLIN 9 (contract line item number 9) of the
19C BARDA Contract have been exercised. SIGA’s full 19C BARDA Contract has up to $414 million of procurement-related options remaining for future exercise.
“The intent of the Request for Proposal for this BARDA Contract was to maintain the existing stockpile of TPOXX and the exercise of these options is an important step toward ensuring that the U.S. Government can
effectively meet this critical goal,” said Dr. Phil Gomez, CEO of SIGA Technologies. “The ongoing COVID-19 pandemic has dramatically underscored the importance of national preparedness. The exercise emphasizes the critical value of our smallpox
anti-viral treatment in that effort, and underscores SIGA’s commitment to working with BARDA and the Office of the Assistant Secretary for Preparedness and Response (ASPR) to protect against the threat of a potential smallpox outbreak or bioterror
attack.”
1
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX
®
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks
(biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX
®
, also known as tecovirimat and ST-246
®
, an orally administered and IV formulation antiviral drug
for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of TPOXX in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was
approved by the FDA for the treatment of smallpox in 2018. The full label is here
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf
. In September 2018, SIGA signed a contract of more than $600 million with the
Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related
to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.
About Smallpox
1
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally-occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global
immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's
side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known
and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the
realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year
ended December 31, 2019, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those
documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no
obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
1
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
2
Contacts:
Investors
David Carey
212-867-1768
david.carey@finnpartners.com
Media
Stephanie Seiler
206-713-0124
stephanie.seiler@finnpartners.com
3